Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

p> patients. Preliminary data from this trial will be presented at the

American Society of Clinical Oncology meeting in June.

Genzyme is developing a new filing for the adult AML indication in

Europe. This follows its withdrawal of Bioenvision's marketing

application, which, as expected, an advisory committee deemed

insufficient to support approval. Genzyme expects to make a new

submission as early as the fourth quarter of this year that will

include a more robust data package from Genzyme sponsored studies.

Alemtuzumab for multiple sclerosis

-- Final, three-year efficacy and safety data from the Phase 2 trial

comparing alemtuzumab with Rebif (interferon beta-1a) for the treatment

of relapsing-remitting multiple sclerosis were presented last week

during a scientific platform session at the American Academy of

Neurology meeting by Dr. Alasdair Coles. These results confirm all

trends observed in the one- and two-year interim analyses. The two

ongoing Phase 3 trials further examining the efficacy and safety of

alemtuzumab for the treatment of MS are progressing. These two studies

are currently enrolling patients at sites in the United States, Europe,

Latin America and Australia. Genzyme believes that alemtuzumab has the

potential to be the best therapy in a market for MS drugs that is

projected to reach $8-9 billion annually when the treatment is expected

to be ready for launch in 2011-2012. Alemtuzumab is being developed in

collaboration with Bayer Schering Pharma AG, Germany.

Genz-112638 for Gaucher disease

-- Genzyme is making excellent progress in developing the small molecule

Genz-112638, a novel oral therapy intended for the treatment of Gaucher

disease. Initial results released one year ago for the first group of

stud
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The report “Service Quality Management and Telco Customer ... - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines ... forecasting of revenues. , Browse 152 market data ... TOC on “Service Quality Management (SQM) and Telco Customer ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
(Date:12/24/2014)... 2014 GMO corn cases filed across the ... the process of being consolidated in a Kansas federal court ... AG MIR 162 Corn Litigation, MDL No. 2591 in the ... of the Syngenta GMO corn multidistrict litigation (MDL) has been ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... Continuing Resolution Appropriations Act of 2015, which for the ... funding through the Congressionally Directed Medical Research Programs (CDMRP) ... Association (HA), working in conjunction with its allies on ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... biologics ... cancer, CAMBRIDGE, Mass., June 10 Merrimack Pharmaceuticals,Inc., a ... for autoimmune disease and cancer, today announced that it,has raised ... Existing and new investors participated in the financing including,Credit Suisse ...
... BHRT ) today announced that it has received ... the Nasdaq Capital Market. The Company,s,common stock will be ... Market at the opening of business on Wednesday, June ... the Nasdaq Stock Market for,companies with a lower market ...
... June 10 Miltenyi Biotec has,acquired Medic Tools ... strengthens the portfolio in the area of sample,preparation. ... into the product range of instruments, reagents, and ... Boris Stoffel and,Franz G. Bucher, Vice President and ...
Cached Biology Technology:Merrimack Pharmaceuticals Raises $60 Million in Private Financing 2Bioheart, Inc. to Transfer to Nasdaq Capital Market 2Miltenyi Biotec GmbH Acquires Medic Tools AG 2
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research and Markets ... of the "iPhone 5S Fingerprint Sensor - Apple/AuthenTec ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... 2012, Apple introduced the fingerprint reading feature with the ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM announced ... audit to confirm its adherence to current U.S. Food ... to conduct regulated smart device and smart phone application ... research quality. "HITLAB is determined to improve ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... Environmentalists are just as fond of talking about ... "sustainability" has become a buzzword. The problem is that ... have manifold interpretations. Agricultural scientists at the Technische Universitaet ... colleagues in theoretical and applied science they have managed ...
... viral polymerase may provide a new therapeutic target for host-adapted ... "Spread of Infection and Lymphocyte Depletion in Mice Depends on ... of the American Journal of Pathology . Highly ... strain of the influenza virus that has adapted to infect ...
... An innovative approach to brain research developed by ... School at Houston has been selected for funding ... designed to support high-impact, medical investigations. Valentin ... at the UT Medical School at Houston, has ...
Cached Biology News:New tools for sustainable farming 2New tools for sustainable farming 3UT's Valentin Dragoi gets $1.2 million grant for groundbreaking approach to brain research 2UT's Valentin Dragoi gets $1.2 million grant for groundbreaking approach to brain research 3
The LIC Duet™ Mini Adaptor encodes a T7 promoter, lac operator, ribosome binding site (rbs), and an ATG translation initation codon. This adaptor is designed for expression of a target protei...
... these culture chambers produce cell yields in ... range and are useful alternatives to multiple ... mechanical • strength and structural integrity • ... Certified nonpyrogenic and sterilized by gamma irradiation, ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
...
Biology Products: